Correlation Engine 2.0
Clear Search sequence regions


  • female (1)
  • humans (1)
  • lopinavir (6)
  • mass (2)
  • patients (3)
  • plasma (4)
  • prothrombin (3)
  • ritonavir (6)
  • Sizes of these terms reflect their relevance to your search.

    It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19. © 2020 The British Pharmacological Society.

    Citation

    Benjamin Batteux, Sandra Bodeau, Valérie Gras-Champel, Sophie Liabeuf, Jean-Philippe Lanoix, Jean-Luc Schmit, Claire Andréjak, Yoann Zerbib, Guillaume Haye, Kamel Masmoudi, Anne-Sophie Lemaire-Hurtel, Youssef Bennis. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. British journal of clinical pharmacology. 2021 Mar;87(3):1547-1553

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32692462

    View Full Text